Substance

ID:68

Names and Identifiers
IUPAC name
(3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-3-(1H-indol-3-yl)-2-(3-{[(2-methylpropoxy)carbonyl]amino}propanamido)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid
Synonyms
Pentagastrin
Brand Name
Peptavlon
IUPAC Traditional name
peptavlon
Registration numbers
PubChem CID
444007
CAS Number
5534-95-2
PubChem SID
46507747
Properties
Physical Property
Hydrophobicity(logP)
1.6
Molecule Details
Drug Groups
approved
Description
A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [PubChem]
Indication
Used as a diagnostic aid for evaluation of gastric acid secretory function
Pharmacology
Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection.
Affected Organisms
Humans and other mammals
Biotransformation
Primarily hepatic
Absorption
Rapidly absorbed after parenteral administration.
Half Life
10 minutes or less
References
• Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9. [Pubmed]
External Links
• [Wikipedia]
Molecular Spectra
No Data Available
Click here to submit data
References
• Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9. Pubmed
Navigation